SUBSCRIBE
SUBSCRIBE

Autobahn Therapeutics

NEWS
Biotech Beach
Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B
This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.
June 9, 2020
 · 
2 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Biotech Beach
Autobahn Therapeutics to Present at Upcoming Investor Conferences
October 4, 2023
 · 
1 min read
Business
Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress
September 11, 2023
 · 
5 min read
Biotech Beach
Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 6, 2023
 · 
1 min read
Drug Development
Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial
April 18, 2023
 · 
3 min read
Biotech Beach
Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days
March 23, 2023
 · 
1 min read
Drug Development
Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder
November 29, 2022
 · 
4 min read
Biotech Beach
Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression
September 8, 2022
 · 
5 min read
Drug Development
Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination
May 18, 2022
 · 
3 min read
Biotech Beach
Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting
March 3, 2022
 · 
3 min read
Biotech Beach
Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders
November 3, 2021
 · 
4 min read
Load More